PE20142322A1 - Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc - Google Patents

Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc

Info

Publication number
PE20142322A1
PE20142322A1 PE2014001908A PE2014001908A PE20142322A1 PE 20142322 A1 PE20142322 A1 PE 20142322A1 PE 2014001908 A PE2014001908 A PE 2014001908A PE 2014001908 A PE2014001908 A PE 2014001908A PE 20142322 A1 PE20142322 A1 PE 20142322A1
Authority
PE
Peru
Prior art keywords
gcc
seq
amino acids
antibody molecules
targeted therapy
Prior art date
Application number
PE2014001908A
Other languages
English (en)
Inventor
Helen Alison Frank
Alice A Mcdonald
Theresa L O'keefe
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of PE20142322A1 publication Critical patent/PE20142322A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase

Abstract

SE REFIERE A ANTICUERPOS Y FRAGMENTOS DE ENLACE DE ANTIGENO DE ANTICUERPOS QUE ENLAZAN GCC, EN EL QUE LOS ANTICUERPOS COMPRENDEN: A) TRES REGIONES DETERMINANTES DE COMPLEMENTARIEDAD DE CADENA PESADA CDR1, CDR2 Y CDR3 CUYAS SECUENCIAS DE AMINOACIDOS SON LAS SEC ID N�: 21, 22 Y 23, O SEC ID N�: 33, 34 Y 35, RESPECTIVAMENTE; B) TRES REGIONES DETERMINANTES DE COMPLEMENTARIEDAD DE CADENA LIGERA CDR1, CDR2 Y CDR3 CUYAS SECUENCIAS DE AMINOACIDOS SON LAS SEC ID N�: 27, 28 Y 29, O SEC ID N�: 39, 40 Y 41, RESPECTIVAMENTE; C) UNA REGION VARIABLE DE CADENA PESADA QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEC ID N�: 11 O 15; Y D) UNA REGION VARIABLE DE CADENA LIGERA QUE TIENE LA SECUENCIA DE AMINOACIDOS DE SEC ID N�: 13 O 17. TAMBIEN SE REFIERE A METODOS DE DIAGNOSTICO PARA IDENTIFICAR PACIENTES QUIENES DEBEN RECIBIR UNA TERAPIA DIRIGIDA A GCC UTILIZANDO LOS ANTICUERPOS ANTI-GCC PROPORCIONADOS EN LA PRESENTE INVENCION
PE2014001908A 2012-04-27 2013-04-27 Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc PE20142322A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261639376P 2012-04-27 2012-04-27

Publications (1)

Publication Number Publication Date
PE20142322A1 true PE20142322A1 (es) 2015-01-25

Family

ID=49477498

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2014001908A PE20142322A1 (es) 2012-04-27 2013-04-27 Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc

Country Status (41)

Country Link
US (3) US9000129B2 (es)
EP (1) EP2841575B1 (es)
JP (2) JP6472746B2 (es)
KR (1) KR102046435B1 (es)
CN (1) CN104395470B (es)
AR (1) AR090884A1 (es)
AU (1) AU2013251312B2 (es)
CA (1) CA2871614C (es)
CL (1) CL2014002911A1 (es)
CO (1) CO7280144A2 (es)
CR (1) CR20140497A (es)
CY (1) CY1122557T1 (es)
DK (1) DK2841575T3 (es)
DO (1) DOP2014000242A (es)
EA (1) EA034689B1 (es)
EC (1) ECSP14028523A (es)
ES (1) ES2749181T3 (es)
GE (1) GEP201706737B (es)
HK (1) HK1208049A1 (es)
HR (1) HRP20191690T1 (es)
HU (1) HUE046404T2 (es)
IL (1) IL235307B (es)
LT (1) LT2841575T (es)
MA (1) MA37569B1 (es)
ME (1) ME03560B (es)
MX (1) MX362020B (es)
MY (1) MY188442A (es)
NZ (1) NZ701601A (es)
PE (1) PE20142322A1 (es)
PH (1) PH12014502399A1 (es)
PL (1) PL2841575T3 (es)
PT (1) PT2841575T (es)
RS (1) RS59370B1 (es)
SA (1) SA113340502B1 (es)
SG (1) SG11201406855TA (es)
SI (1) SI2841575T1 (es)
TN (1) TN2014000454A1 (es)
TW (1) TWI631137B (es)
UA (1) UA117910C2 (es)
WO (1) WO2013163633A1 (es)
ZA (1) ZA201407723B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101834890B1 (ko) 2009-10-23 2018-04-20 밀레니엄 파머슈티컬스 인코퍼레이티드 항­ｇｃｃ 항체 분자와 관련 조성물 및 방법
US20160264663A1 (en) * 2013-10-21 2016-09-15 The Centre For Drug Research And Development Anti-podocalyxin antibodies and methods of using the same
JP6496962B2 (ja) 2014-02-14 2019-04-10 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ アセトアミノフェン−タンパク質付加物およびその使用方法
JP6785239B2 (ja) 2014-12-03 2020-11-18 バイオベンチャーズ・リミテッド・ライアビリティ・カンパニーＢｉｏＶｅｎｔｕｒｅｓ， ＬＬＣ 抗アセトアミノフェン抗体及びアセトアミノフェンタンパク質付加物
CN109311994B (zh) 2015-10-01 2022-06-07 药物研究及发展中心 抗足糖萼蛋白抗体及其使用方法
KR102080887B1 (ko) * 2017-11-07 2020-02-24 고려대학교 산학협력단 Gcc2 유전자 또는 단백질을 과발현하는 엑소좀 기반 폐암 진단 또는 예후 예측용 마커 조성물
WO2019110561A1 (en) * 2017-12-06 2019-06-13 Ventana Medical Systems, Inc. Method of storing and retrieving digital pathology analysis results
US11568657B2 (en) 2017-12-06 2023-01-31 Ventana Medical Systems, Inc. Method of storing and retrieving digital pathology analysis results
WO2020050722A1 (en) * 2018-09-05 2020-03-12 Universiteit Van Amsterdam Use of a pde11 or pde2 inhibitor for the treatment of parkinson's disease
WO2021205325A1 (en) * 2020-04-08 2021-10-14 Pfizer Inc. Anti-gucy2c antibodies and uses thereof
EP4159860A1 (en) * 2020-06-02 2023-04-05 Teijin Pharma Limited Anti-igf-1 receptor humanized antibody
WO2022127871A1 (en) * 2020-12-17 2022-06-23 Parasol Biotech Ltd. Gucy2c binding molecules and uses thereof
WO2024067762A1 (en) * 2022-09-28 2024-04-04 Nanjing Legend Biotech Co., Ltd. Antibody and chimeric antigen receptors targeting gcc and methods of use thereof
CN116535514B (zh) * 2023-06-15 2024-02-02 上海斯丹赛生物技术有限公司 抗鸟苷酸环化酶c抗体及其在癌症治疗中的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5237051A (en) 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
US5518888A (en) 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US7097839B1 (en) 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US5879656A (en) 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US6060037A (en) 1993-10-26 2000-05-09 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US5601990A (en) 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US6455251B1 (en) 1994-09-13 2002-09-24 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
WO1997042506A1 (en) 1996-05-03 1997-11-13 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
EP0951475B1 (en) 1996-05-03 2003-07-16 Thomas Jefferson University Metastatic colorectal cancer vaccine
US6120995A (en) 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
US8092514B1 (en) 1998-11-16 2012-01-10 Boston Scientific Scimed, Inc. Stretchable anti-buckling coiled-sheet stent
US20040031072A1 (en) 1999-05-06 2004-02-12 La Rosa Thomas J. Soy nucleic acid molecules and other molecules associated with transcription plants and uses thereof for plant improvement
EP1268854A4 (en) 2000-03-27 2003-05-02 Univ Jefferson HIGH SPECIFICITY MARKER DETECTION
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
MXPA03006651A (es) 2001-01-26 2004-11-12 Inhibitex Inc Anticuerpos monoclonales para la proteina clfa y metodos para el uso en el tratamiento o prevencion de infecciones.
EA006651B1 (ru) 2001-03-29 2006-02-24 Синерджи Фармасьютикалз, Инк. Агонисты гуанилатциклазного рецептора для лечения тканевого воспаления и канцерогенеза
IL158376A0 (en) 2001-04-13 2004-05-12 Biogen Inc Antibodies to vla-1
ES2289174T3 (es) 2001-12-28 2008-02-01 Amgen Fremont Inc. Anticuerpos contra el antigeno muc-18.
US20040110933A1 (en) 2002-09-13 2004-06-10 Dyax Corporation CD44-binding ligands
DE10254601A1 (de) 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1599165A4 (en) 2003-02-10 2010-09-08 Univ Jefferson THE USE OF GCC LIGANDS
EP1627062A1 (en) 2003-05-14 2006-02-22 Domantis Limited A process for recovering polypeptides that unfold reversibly from a polypeptide repertoire
US7871610B2 (en) 2003-08-12 2011-01-18 Dyax Corp. Antibodies to Tie1 ectodomain
EP1781339B1 (en) 2004-06-25 2013-12-25 Thomas Jefferson University Guanylyl cyclase C ligands
EP2284194A1 (en) 2004-12-21 2011-02-16 AstraZeneca AB Antibodies directed to angiopoietin-2 and uses thereof
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
US7879802B2 (en) 2007-06-04 2011-02-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
BRPI0814355A2 (pt) * 2007-08-10 2015-01-27 Centocor Ortho Biotech Inc Fragmentos de clivagem de imunoglobulina como indicadores de doença e composições para detecção e ligação dos mesmos
PT2187964E (pt) 2007-08-10 2015-01-14 Regeneron Pharma Anticorpos humanos de elevada afinidade para o factor de crescimento neural humano
EP2220492B1 (en) * 2007-11-30 2011-08-31 Genentech, Inc. Vegf polymorphisms and anti-angiogenesis therapy
CA2760050A1 (en) 2008-05-13 2009-11-19 Thomas Jefferson University Guanylyl cyclase c qrt-pcr
CA2726913C (en) 2008-06-04 2020-02-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP2370098A4 (en) 2008-12-03 2013-07-17 Morphosys Ag ANTIBODIES FOR GUANYLYLCYCLASE RECEPTORS
CA2744236C (en) * 2009-02-12 2021-03-16 Cell Signaling Technology, Inc. Mutant ros expression in human cancer
EP2401394B1 (en) 2009-02-25 2013-11-27 Diagnocure Inc. Method for detecting metastasis of gi cancer
EP2407786A4 (en) * 2009-03-12 2013-01-02 Univ Kinki METHOD FOR PREDICTING THE THERAPEUTIC EFFICACY OF CHEMOTHERAPY ON NON-SMALL CELL LUNG CANCER
WO2010147684A1 (en) 2009-06-15 2010-12-23 Thomas Jefferson University Compositions for and methods of activating guanylyl cyclase c
EP2491116A4 (en) 2009-10-22 2013-12-11 Univ Jefferson CELL-BASED ANTI-RISK COMPOSITIONS AND METHOD FOR THEIR PREPARATION AND USE
KR101834890B1 (ko) * 2009-10-23 2018-04-20 밀레니엄 파머슈티컬스 인코퍼레이티드 항­ｇｃｃ 항체 분자와 관련 조성물 및 방법
WO2011150454A1 (en) * 2010-06-01 2011-12-08 Monash University ANTIBODIES DIRECTED TO THE UNPROCESSED RECEPTOR TYROSINE KINASE c-MET
WO2012020123A2 (en) * 2010-08-13 2012-02-16 F. Hoffmann-La Roche Ag Neuropilin as a biomarker for bevacizumab combination therapies
US20150086481A1 (en) 2011-07-28 2015-03-26 Memorial Sloan-Kettering Cancer Center Diagnosis and treatment of parkinson's disease
US9156915B2 (en) 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
TW201444577A (zh) * 2013-02-28 2014-12-01 Millennium Pharm Inc 投予抗－ｇｃｃ抗體－藥物共軛物及ｄｎａ破壞劑來治療癌症

Also Published As

Publication number Publication date
US20160130344A1 (en) 2016-05-12
CR20140497A (es) 2015-02-10
MA37569B1 (fr) 2020-08-31
TW201348258A (zh) 2013-12-01
HK1208049A1 (en) 2016-02-19
CN104395470A (zh) 2015-03-04
JP6517267B2 (ja) 2019-05-22
CN104395470B (zh) 2018-02-06
KR102046435B1 (ko) 2019-11-19
KR20150004882A (ko) 2015-01-13
CA2871614C (en) 2021-08-31
SG11201406855TA (en) 2014-11-27
TN2014000454A1 (en) 2016-03-30
SA113340502B1 (ar) 2015-09-17
AU2013251312A1 (en) 2014-10-30
HRP20191690T1 (hr) 2019-12-27
NZ701601A (en) 2016-09-30
JP2015516985A (ja) 2015-06-18
DK2841575T3 (da) 2019-09-23
ES2749181T3 (es) 2020-03-19
JP2017131245A (ja) 2017-08-03
GEP201706737B (en) 2017-09-25
ZA201407723B (en) 2019-01-30
IL235307B (en) 2019-07-31
EA034689B1 (ru) 2020-03-06
BR112014026742A2 (pt) 2017-07-11
JP6472746B2 (ja) 2019-02-20
CL2014002911A1 (es) 2015-01-30
DOP2014000242A (es) 2014-11-30
ME03560B (me) 2020-07-20
SI2841575T1 (sl) 2019-11-29
US20130287783A1 (en) 2013-10-31
IL235307A0 (en) 2014-12-31
US9000129B2 (en) 2015-04-07
PT2841575T (pt) 2019-10-11
MX362020B (es) 2019-01-04
PH12014502399B1 (en) 2014-12-22
UA117910C2 (uk) 2018-10-25
TWI631137B (zh) 2018-08-01
ECSP14028523A (es) 2015-09-30
RS59370B1 (sr) 2019-11-29
AR090884A1 (es) 2014-12-10
CA2871614A1 (en) 2013-10-31
LT2841575T (lt) 2019-10-10
EA201491977A1 (ru) 2015-04-30
CY1122557T1 (el) 2021-01-27
US9273146B1 (en) 2016-03-01
EP2841575A4 (en) 2016-06-15
MX2014013081A (es) 2015-01-12
AU2013251312B2 (en) 2018-03-22
CO7280144A2 (es) 2015-05-29
WO2013163633A1 (en) 2013-10-31
MY188442A (en) 2021-12-09
HUE046404T2 (hu) 2020-02-28
EP2841575B1 (en) 2019-06-26
PH12014502399A1 (en) 2014-12-22
PL2841575T3 (pl) 2020-01-31
EP2841575A1 (en) 2015-03-04

Similar Documents

Publication Publication Date Title
PE20142322A1 (es) Moleculas de anticuerpo anti-gcc y uso de las mismas para probar la susceptibilidad a la terapia dirigida a gcc
CY1121392T1 (el) Μορια δεσμευσης εναντι-αλφα συνουκλεϊνης
CL2018003583A1 (es) Anticuerpos anti-pd-l1 y usos de los mismos.
CY1123518T1 (el) Ανθρωπινα αντισωματα enanti-tau
CY1120414T1 (el) Αντισωματα που συνδεονται me οχ40 και οι χρησεις τους
CY1122020T1 (el) Μορια δεσμευσης σε cd3 ικανα να δεσμευονται σε ανθρωπινα και μη ανθρωπινα cd3
ECSP18043564A (es) Moléculas biespecíficas que tienen inmunorreactividad con pd-1 y ctla-4, y métodos de uso de las mismas
NZ773949A (en) Anti-pdl1 antibodies, activatable anti-pdl1 antibodies, and methods of use thereof
ECSP17005649A (es) Anticuerpos anti-tau humanizados
AR117911A2 (es) Anticuerpo anti-158p1d7 o fragmento de unión a antígeno del mismo, conjugado fármaco-anticuerpo, composición farmacéutica y sus usos
AR109715A1 (es) Anticuerpos anti-cd27
ECSP16060104A (es) Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este
EA201591091A1 (ru) Антигенсвязывающие белки для bcma
PE20110797A1 (es) Anticuerpos anti mn
NZ727024A (en) Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
EA201490825A8 (ru) Tdp-43-специфически связывающие молекулы
NZ706377A (en) Il-6 antagonists and uses thereof
PE20180042A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
GT201200318A (es) Anticuerpos hacia gdf8 humano
AR095980A1 (es) Anticuerpos biespecíficos específicos para fap (proteína de activación fibroblástica) y dr5 (receptor de muerte 5), anticuerpos específicos para dr5 y métodos de utilización
PE20140448A1 (es) Moleculas de union biespecificas que se unen a vegf y ang2
ECSP13012436A (es) ANTICUERPOS PEPTÍDICOS BETA AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
NZ629829A (en) Anti-c5a antibodies and methods for using the antibodies
PE20210377A1 (es) Anticuerpos anti-pd-l1 y usos de los mismos
PE20151289A1 (es) Anticuerpos que se unen al tl1a y sus usos

Legal Events

Date Code Title Description
FG Grant, registration